FDA Approval Status & Compounding Checker
Verify approval, investigation, compounding, and anti-doping classifications.
| Peptide / Brand | FDA Status | Clinical Indication / Scope | 503A Compounding Law | WADA Status |
|---|---|---|---|---|
| Semaglutide Ozempic, Wegovy, Rybelsus GLP-1 Receptor Agonist | FDA Approved | T2D Glycemic Control, Chronic Weight Management, MACE CVD Risk Reduction | Prescription only; restricted compounding post-shortage resolution | Not Prohibited |
| Tirzepatide Mounjaro, Zepbound Dual GIP / GLP-1 Agonist | FDA Approved | T2D Glycemic Control, Chronic Weight Management | Prescription only; subject to ongoing patent litigation | Not Prohibited |
| Liraglutide Victoza, Saxenda GLP-1 Receptor Agonist | FDA Approved | T2D Glycemic Control, Chronic Weight Management | Prescription only; generic versions under review | Not Prohibited |
| Retatrutide LY3437943 (Investigational) Triple Agonist (GLP-1/GIP/Glucagon) | Phase 3 Investigational | Investigational: Severe Obesity, T2D, MASH | Illegal to compound outside authorized clinical trials | Prohibited (S0 Non-Approved) |
| BPC-157 PL 14736, Bepecin Gastric Pentadecapeptide | FDA 503A Restricted (Category 2) | Preclinical: Tissue & Gut Repair (No FDA Approved Indication) | Banned from 503A pharmacy compounding due to safety risks | Prohibited (S0 Non-Approved) |
| TB-500 Thymosin Beta-4 Fragment Actin-Sequestering Peptide | FDA 503A Restricted (Category 2) | Preclinical: Tissue Regeneration, Wound Repair | Banned from 503A pharmacy compounding | Prohibited (S2 Growth Factors) |
| CJC-1295 Mod GRF 1-29, DAC:GRF GHRH Analog | FDA 503A Restricted (Category 2) | Investigational: Growth Hormone Secretagogue | Banned from 503A pharmacy compounding | Prohibited (S2 Peptide Hormones) |
| Ipamorelin NNC 26-0161 GHRP Secretagogue | FDA 503A Restricted (Category 2) | Investigational: Postoperative Bowel Function (Discontinued) | Banned from 503A pharmacy compounding | Prohibited (S2 Growth Factors) |
| Tesamorelin Egrifta, Egrifta SV Stabilized GHRH Analog | FDA Approved | HIV-Associated Lipodystrophy (Visceral Adiposity) | Available via commercial prescription (Rx only) | Prohibited in Competition (S2) |
| Sermorelin Geref (Historical) GHRH (1-29) | FDA Approved / 503A Category 1 | Diagnostic Evaluation of Pituitary GH Function | Permitted under valid 503A patient-specific prescription | Prohibited (S2 Peptide Hormones) |
| Bremelanotide (PT-141) Vyleesi MC4R Agonist | FDA Approved | Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women | Prescription only (auto-injector format) | Not Prohibited |
| Melanotan II MT-2 Non-Selective Melanocortin Agonist | FDA Banned / Unlawful | None (Associated with Severe Toxicities & Melanoma Risk) | Completely illegal for human compounding or sales | Prohibited (S0 Non-Approved) |
| GHK-Cu Copper Tripeptide-1 Copper Chelate Tripeptide | Cosmetic Ingredient | Cosmetic: Topical Skin Remodeling (Unapproved as Injectable) | Topical compounding permissible; unapproved as injectable | Not Prohibited |
| MOTS-c Mitochondrial 12S rRNA-c Mitochondrial-Derived Peptide | FDA 503A Restricted (Category 2) | Preclinical: Metabolic Signaling & AMPK Activation | Banned from 503A compounding | Prohibited (S2 Metabolic Modulators) |
| SS-31 (Elamipretide) Bendavia (Investigational) Mitochondrial Cardiolipin Stabilizer | Phase 3 Investigational (FDA Fast Track) | Investigational: Barth Syndrome, Mitochondrial Myopathy | Illegal outside authorized clinical trials | Prohibited (S0 Non-Approved) |
| Epitalon Epithalamin Synthetic Synthetic Pineal Tetrapeptide | Unapproved / Category 2 | Preclinical: Telomerase Induction (No Human Phase 3 Data) | Restricted from 503A compounding | Prohibited (S0 Non-Approved) |